14 14

Cited 0 times in

Efficacy and Safety of Ghrelin Agonists in Patients with Diabetic Gastroparesis: A Systematic Review and Meta-Analysis

Authors
 Seung Wook Hong  ;  Jaeyoung Chun  ;  Jihye Kim  ;  Jooyoung Lee  ;  Hyun Jung Lee  ;  Hyunsoo Chung  ;  Soo-Jeong Cho  ;  Jong Pil Im  ;  Sang Gyun Kim  ;  Joo Sung Kim 
Citation
 GUT AND LIVER, Vol.14(5) : 589-600, 2020-09 
Journal Title
 GUT AND LIVER 
ISSN
 1976-2283 
Issue Date
2020-09
Keywords
Diabetes mellitus ; Gastroparesis ; Ghrelin ; Meta analysis ; Systematic review
Abstract
Background/aims: Ghrelin agonists are emerging prokinetic agents for treating gastroparesis. Although recent clinical trials have demonstrated their efficacy in patients with diabetic gastroparesis (DG), the impact of such agents on symptoms and gastric dysmotility remains unclear. We performed a systematic review and meta-analysis to evaluate the efficacy and safety of ghrelin agonists in patients with DG. Methods: A search of common electronic databases (MEDLINE, Embase, and Cochrane Central Register of Controlled Trials) was preformed, using keyword combinations that referenced ghrelin and DG and retrieving all eligible randomized controlled trials (RCTs) of ghrelin agonists versus placebo in patients with DG. The primary outcome measure was the change in patient-reported overall gastroparesis symptom scores. Secondary outcomes included the change in gastric emptying time, specific symptoms related to gastroparesis, and adverse events. A random-effects model was applied to all study outcomes. Heterogeneity among studies was determined by the chi-square test and I2 statistics. Results: We selected six RCTs of patients with DG (n=557) for meta-analysis. Ghrelin agonist administration (vs placebo) significantly improved overall gastroparesis symptoms (standardized mean difference, -0.34; 95% confidence interval, -0.56 to -0.13) and significantly improved symptoms related to gastroparesis, including nausea, vomiting, early satiety, and abdominal pain. Adverse events recorded for ghrelin agonists and placebo did not differ significantly. There was no significant heterogeneity among eligible studies. Conclusions: Compared with placebo, ghrelin agonists are effective and well-tolerated for the treatment of DG.
Files in This Item:
T202003641.pdf Download
DOI
10.5009/gnl19103
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Chun, Jaeyoung(천재영) ORCID logo https://orcid.org/0000-0002-4212-0380
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/180020
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links